ArticleScientific reports2026
Enhanced oral delivery and bioactivity of EGCG via DNA nanocarriers.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Herein we describe epigallocatechin gallate (EGCG), a bioactive green tea extract, loading onto DNA nanostructures [DNA tetrahedron (TDNs) and DNA hydrogel (DH)] for improved bioavailability and biological activity. TDN-EGCG incorporation was confirmed by circular dichroism (CD), UV spectroscopy and gel electrophoresis (PAGE). Degradation kinetics of TDN and DH, with and without EGCG were measured for up to 14 days and quantified by PAGE. TDN-EGCG showed slower degradation than TDN in human saliva, while both nanostructures remained stable in artificial saliva for up to 48 h. DH-EGCG showed improved stability compared to the hydrogel alone. Human gingival fibroblasts exposed to neat-EGCG, TDN-EGCG, TDN, or buffer were analyzed for cell viability, total protein quantification, and cytokines expression levels. Cell viability and total protein levels did not differ from controls. The inhibitory effect of TDN and TDN-EGCG on Streptococcus mutans biofilms was also investigated. TDN-EGCG reduced IL-6, IL-8, and MCP-1 at 6 h and IL-6 and MCP-1 at 24 h timepoints, and inhibited S. mutans biofilm formation after 6 h. Statistical analyses were performed using one-way ANOVA and Tukey's post-hoc test (α = 0.05). These findings highlight TDNs as promising EGCG carriers and support DH-EGCG as a complementary delivery system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.